Evidence map›Paper›PMID 28425497›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2017

Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.

Gregory A Light, Wen Zhang, Yash B Joshi, Savita Bhakta, Jo A Talledo, Neal R Swerdlow

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Glutamatergic Modulation of Brain Function in Psychosis: A Systematic Review of Neuroimaging Studies.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2025
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Memantine effects on auditory discrimination and training in schizophrenia patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Trial
  7. Trial
  8. Trial
  9. Neurophysiologic measures of target engagement predict response to auditory-based cognitive training in treatment refractory schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019
    Trial
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. 40 Hz Steady-State Response in Human Auditory Cortex Is Shaped by Gabaergic Neuronal Inhibition.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gregory A LightVISN-22 Mental Illness Research Education and Clinical Center, VA San Diego Healthcare System, San Diego, CA, USA.
Wen ZhangVISN-22 Mental Illness Research Education and Clinical Center, VA San Diego Healthcare System, San Diego, CA, USA.
Yash B JoshiVISN-22 Mental Illness Research Education and Clinical Center, VA San Diego Healthcare System, San Diego, CA, USA.
Savita BhaktaVISN-22 Mental Illness Research Education and Clinical Center, VA San Diego Healthcare System, San Diego, CA, USA.ORCID http://orcid.org/0000-0001-5560-8011
Jo A TalledoVISN-22 Mental Illness Research Education and Clinical Center, VA San Diego Healthcare System, San Diego, CA, USA.
Neal R SwerdlowVISN-22 Mental Illness Research Education and Clinical Center, VA San Diego Healthcare System, San Diego, CA, USA.

Funding

UC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4M
Pharmacologic augmentation of neurocognition and cognitive training in psychosisR01MH059803 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SWERDLOW, NEAL R · 1999 to 2018
$4.5M
Psychiatry Research Residency Training TrackR25MH101072 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NEAL R SWERDLOW · 2013 to 2026
$2.8M
Memantine effects on sensorimotor gating and neurocognition in schizophreniaR01MH094320 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SWERDLOW, NEAL R · 2012 to 2020
$2.6M
NCATS NIH HHS KL2 TR001444NIMH NIH HHS R01 MH059803NIMH NIH HHS R01 MH094320NIMH NIH HHS R25 MH101072
6 · The paper itself

Abstract

Aberrant gamma-band (30-80 Hz) oscillations may underlie cognitive deficits in schizophrenia (SZ). Gamma oscillations and their regulation by NMDA receptors can be studied via their evoked power (γEP) and phase locking (γPL) in response to auditory steady-state stimulation; these auditory steady-state responses (ASSRs) may be biomarkers for target engagement and early therapeutic effects. We previously reported that memantine, an NMDA receptor antagonist, enhanced two biomarkers of early auditory information processing: prepulse inhibition and mismatch negativity (MMN) in SZ patients and healthy subjects (HS). Here, we describe memantine effects on γEP and γPL in those subjects. SZ patients (n=18) and HS (n=14) received memantine 20 mg (p.o.) and placebo over 2 test days in a double-blind, randomized, counterbalanced, cross-over design. The ASSR paradigm (1 ms, 85 dB clicks in 250-0.5 s trains at a frequency of 40 Hz; 0.5 s inter-train interval) was used to assess γEP and γPL. SZ patients had reduced γEP and γPL; memantine enhanced γEP and γPL (p<0.025 and 0.002, respectively) in both SZ and HS. In patients, significant correlations between age and memantine effects were detected for γEP and γPL: greater memantine sensitivity on γEP and γPL were present in younger SZ patients, similar to our reported findings with MMN. Memantine acutely normalized cortical oscillatory dynamics associated with NMDA receptor dysfunction in SZ patients. Ongoing studies will clarify whether these acute changes predict beneficial clinical, neurocognitive and functional outcomes. These data support the use of gamma-band ASSR as a translational end point in pro-cognitive drug discovery and early-phase clinical trials.

Indexed as

AdultAntipsychotic AgentsAuditory PerceptionChronic DiseaseCortical SynchronizationCross-Over StudiesDepressive DisorderDouble-Blind MethodExcitatory Amino Acid AntagonistsFemaleGamma RhythmHumansMaleMemantineMiddle AgedPrepulse InhibitionAntipsychotic AgentsExcitatory Amino Acid AntagonistsMemantineReceptors, N-Methyl-D-Aspartate

Identifiers

PMID28425497
PMCPMC5686499

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.